538 related articles for article (PubMed ID: 18367459)
21. Infections caused by carbapenem-resistant Gram-negative pathogens in hospitalized children.
Maltezou HC; Kontopidou F; Katerelos P; Daikos G; Roilides E; Theodoridou M
Pediatr Infect Dis J; 2013 Apr; 32(4):e151-4. PubMed ID: 23249908
[TBL] [Abstract][Full Text] [Related]
22. Successful treatment of skin and soft tissue infection due to carbapenem-resistant Acinetobacter baumannii by ampicillin-sulbactam and meropenem combination therapy.
Hiraki Y; Yoshida M; Masuda Y; Inoue D; Tsuji Y; Kamimura H; Karube Y; Takaki K; Kawano F
Int J Infect Dis; 2013 Dec; 17(12):e1234-6. PubMed ID: 23791858
[TBL] [Abstract][Full Text] [Related]
23. Risk factors for nosocomial imipenem-resistant Acinetobacter baumannii infections.
Baran G; Erbay A; Bodur H; Ongürü P; Akinci E; Balaban N; Cevik MA
Int J Infect Dis; 2008 Jan; 12(1):16-21. PubMed ID: 17513154
[TBL] [Abstract][Full Text] [Related]
24. Bloodstream infections caused by Enterobacter species: predictors of 30-day mortality rate and impact of broad-spectrum cephalosporin resistance on outcome.
Kang CI; Kim SH; Park WB; Lee KD; Kim HB; Oh MD; Kim EC; Choe KW
Clin Infect Dis; 2004 Sep; 39(6):812-8. PubMed ID: 15472813
[TBL] [Abstract][Full Text] [Related]
25. Exposure to quinolones is associated with carbapenem resistance among colistin-susceptible Acinetobacter baumannii blood isolates.
Kopterides P; Koletsi PK; Michalopoulos A; Falagas ME
Int J Antimicrob Agents; 2007 Nov; 30(5):409-14. PubMed ID: 17851052
[TBL] [Abstract][Full Text] [Related]
26. Prognosis of adult patients with bacteremia caused by extensively resistant Acinetobacter baumannii.
Tseng YC; Wang JT; Wu FL; Chen YC; Chie WC; Chang SC
Diagn Microbiol Infect Dis; 2007 Oct; 59(2):181-90. PubMed ID: 17662564
[TBL] [Abstract][Full Text] [Related]
27. High mortality associated with Acinetobacter species infection in liver transplant patients.
Kim YJ; Yoon JH; Kim SI; Hong KW; Kim JI; Choi JY; Yoon SK; You YK; Lee MD; Moon IS; Kim DG; Kang MW
Transplant Proc; 2011; 43(6):2397-9. PubMed ID: 21839276
[TBL] [Abstract][Full Text] [Related]
28. Combination carbapenem-sulbactam therapy for critically ill patients with multidrug-resistant Acinetobacter baumannii bacteremia: four case reports and an in vitro combination synergy study.
Lee NY; Wang CL; Chuang YC; Yu WL; Lee HC; Chang CM; Wang LR; Ko WC
Pharmacotherapy; 2007 Nov; 27(11):1506-11. PubMed ID: 17963460
[TBL] [Abstract][Full Text] [Related]
29. [Analysis of clinical characteristics and antimicrobial resistance of carbapenem-resistant Acinetobacter baumannii infections in children].
Zhang TQ; Dong L; Wang ZY; Li HY
Zhonghua Er Ke Za Zhi; 2011 Jul; 49(7):545-9. PubMed ID: 22088187
[TBL] [Abstract][Full Text] [Related]
30. Risk factors for candidemia-related mortality at a medical center in central Taiwan.
Cheng YR; Lin LC; Young TG; Liu CE; Chen CH; Tsay RW
J Microbiol Immunol Infect; 2006 Apr; 39(2):155-61. PubMed ID: 16604249
[TBL] [Abstract][Full Text] [Related]
31. The significance of Acinetobacter baumannii bacteraemia compared with Klebsiella pneumoniae bacteraemia: risk factors and outcomes.
Robenshtok E; Paul M; Leibovici L; Fraser A; Pitlik S; Ostfeld I; Samra Z; Perez S; Lev B; Weinberger M
J Hosp Infect; 2006 Nov; 64(3):282-7. PubMed ID: 16930770
[TBL] [Abstract][Full Text] [Related]
32. Risk factors and clinical outcomes of patients with carbapenem-resistant Acinetobacter baumannii bacteremia.
Huang ST; Chiang MC; Kuo SC; Lee YT; Chiang TH; Yang SP; Ti-Yin ; Chen TL; Fung CP
J Microbiol Immunol Infect; 2012 Oct; 45(5):356-62. PubMed ID: 22575430
[TBL] [Abstract][Full Text] [Related]
33. Therapeutic options for Acinetobacter baumannii infections.
Vila J; Pachón J
Expert Opin Pharmacother; 2008 Mar; 9(4):587-99. PubMed ID: 18312160
[TBL] [Abstract][Full Text] [Related]
34. Inflammatory response and clinical course of adult patients with nosocomial bloodstream infections caused by Candida spp.
Wisplinghoff H; Seifert H; Wenzel RP; Edmond MB
Clin Microbiol Infect; 2006 Feb; 12(2):170-7. PubMed ID: 16441456
[TBL] [Abstract][Full Text] [Related]
35. Trimethoprim-sulfamethoxazole vs. colistin or ampicillin-sulbactam for the treatment of carbapenem-resistant Acinetobacter baumannii: A retrospective matched cohort study.
Raz-Pasteur A; Liron Y; Amir-Ronen R; Abdelgani S; Ohanyan A; Geffen Y; Paul M
J Glob Antimicrob Resist; 2019 Jun; 17():168-172. PubMed ID: 30557685
[TBL] [Abstract][Full Text] [Related]
36. Attributable mortality of imipenem-resistant nosocomial Acinetobacter baumannii bloodstream infection.
Jamulitrat S; Arunpan P; Phainuphong P
J Med Assoc Thai; 2009 Mar; 92(3):413-9. PubMed ID: 19301737
[TBL] [Abstract][Full Text] [Related]
37. Time- and fluid-sensitive resuscitation for hemodynamic support of children in septic shock: barriers to the implementation of the American College of Critical Care Medicine/Pediatric Advanced Life Support Guidelines in a pediatric intensive care unit in a developing world.
Oliveira CF; Nogueira de Sá FR; Oliveira DS; Gottschald AF; Moura JD; Shibata AR; Troster EJ; Vaz FA; Carcillo JA
Pediatr Emerg Care; 2008 Dec; 24(12):810-5. PubMed ID: 19050666
[TBL] [Abstract][Full Text] [Related]
38. Risk factors and clinical outcome of sulbactam nonsusceptibility in monomicrobial Acinetobacter nosocomialis bacteremia.
Lai HH; Liou BH; Chang YY; Kuo SC; Lee YT; Chen TL; Fung CP
J Microbiol Immunol Infect; 2016 Jun; 49(3):371-7. PubMed ID: 25081987
[TBL] [Abstract][Full Text] [Related]
39. OXA (beta)-lactamases in Acinetobacter: the story so far.
Brown S; Amyes S
J Antimicrob Chemother; 2006 Jan; 57(1):1-3. PubMed ID: 16332731
[TBL] [Abstract][Full Text] [Related]
40. Impact of carbapenem resistance on clinical and economic outcomes among patients with Acinetobacter baumannii infection in Colombia.
Lemos EV; de la Hoz FP; Alvis N; Einarson TR; Quevedo E; Castañeda C; Leon Y; Amado C; Cañon O; Kawai K
Clin Microbiol Infect; 2014 Feb; 20(2):174-80. PubMed ID: 23668595
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
